ORCHID Annual Report 2024 - Flipbook - Page 22
Digital Profile:
ORCID ID: 000-0001-6090-1650
Research gate profile: https://www.researchgate.net/profile/Ji_Soo_Kim7
Published Abstracts
Kim JS, Wray J, Ridout D, Plimb L, Nitsch D, Robb M, Marks DS. (2024)
Protocol for a multicentre prospective exploratory mixed-methods study
investigating the modifiable psychosocial variables influencing access to and
outcomes after kidney transplantation in children and young people in the UK.
BMJ Open;14: e078150.https://doi.org/10.1136/bmjopen-2023-078150
Peer reviewed publications
Kim JS, Wray J, Ridout D, Plumb L, Nitsch D, Robb M, Marks SD. (2024)
1% recipient cells.
However, leukaemic patients benefit from methods with greater sensitivity
detecting as low as 0.001% cells (= microchimerism). A drop in donor
chimerism and a detectable mutation burden usually precedes leukaemic
relapse. This study will assess when detectable levels of microchimerism
and mutation burden in peripheral blood (PB) and BM can be linked to an
increased relapse risk indicating the use of therapeutic interventions. PB
samples will be further assessed to see if the relapse risk can be monitored
using PB only.
There is currently no data on which level of donor chimerism and mutation
burden post-BMT are associated with a significant relapse risk. Furthermore,
there is no systematic data for the use of therapeutic interventions to prevent
JMML relapse.
The primary objective is to study predictive signs of JMML relapse using
hyper-sensitive laboratory methods. The secondary objective is to compare
results for PB and BM to see if PB analysis alone can indicate early relapse,
leading to a reduction of BM samples being taken. The third objective is to
develop a risk stratification framework guiding proactive therapeutic
interventions.
Study Progress:
The first chapter of my PhD project has been completed which was
examining the significance of microchimerism in JMML patient post BMT.
Macrochimerism analysis has been added to the test repertoire as
characteristic chimerism patterns were observed in groups of relapse and
non-relapse JMML patients. Within the relapse group, a distinct chimerism
pattern was observed in the majority of patients. Monocyte and T cell
chimerism appeared to be key in this pattern. In relapse patients, recipient
chimerism in the monocytic cell lineage was rapidly increasing and was in
fact the PB-derived cell lineage with the highest percentage of recipient cells.
The T cell lineage displayed the lowest level of recipient chimerism. This is in
direct contrast to the monocyte and T cell recipient chimerism observed in
non-relapse cohorts where low monocytic and high T cell RC was observed.
Digital Profile:
ORCiD ID:0000-0003-0791-2291
Research Gate: https://www.researchgate.net/profile/Susanne-Kricke
22
